Buy CJC1295 No DAC (MOD-GRF (1-29)) +Ipamorelin 10 mg (5mg+5mg)

€41.41

CJC-1295 No DAC 5 mg plus Ipamorelin 5 mg is an equimass dual-peptide format for analytical and in vitro laboratory research. Pharma Research .eu provides documented European supply subject to separate CoA and identity verification.

Category:
Description

Buy CJC-1295 No DAC (Mod-GRF (1-29)) + Ipamorelin, 10 mg, for Advanced Laboratory Research in Europe

This 1:1 peptide blend contains 5 mg of CJC-1295 No DAC, also known as Modified GRF (1-29), and 5 mg of Ipamorelin. The components are chemically distinct: CJC-1295 No DAC is a 29-residue amidated GHRH analogue, while Ipamorelin is a five-residue modified peptide. They should be characterised and quantified separately rather than treated as one compound. Pharma Research .eu presents this 10 mg combined format for qualified European laboratories conducting controlled analytical and in vitro research.apexlab+2

Uncompromising Purity and Analytical Characterisation

The blend should be documented as two separate active peptide components.

CJC-1295 No DAC / Modified GRF (1-29) is commonly specified as an amidated 29-residue sequence. One widely reported sequence is:

Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NHβ‚‚

Some catalogues report closely related sequence variants, so the exact sequence and terminal groups must be verified on the batch CoA. The β€œNo DAC” designation is important: it distinguishes this material from DAC-conjugated CJC-1295, which has a different molecular mass and pharmacokinetic design.peptalabs+1

Ipamorelin is commonly specified as:

Aib-His-D-2-Nal-D-Phe-Lys-NHβ‚‚

Here, Aib denotes Ξ±-aminoisobutyric acid and D-2-Nal denotes D-3-(2-naphthyl)alanine. Ipamorelin is therefore a five-residue modified peptide rather than a conventional six-residue sequence.pubchem.ncbi.nlm.nih+2

For procurement, the suitable target is β‰₯99.0% purity by RP-HPLC for each peptide component, subject to confirmation by the actual batch-specific CoA. A blend-level purity figure is insufficient because it may conceal degradation or under-content of one component.

A complete CoA should include:

  • Separate RP-HPLC purity results for CJC-1295 No DAC and Ipamorelin.

  • Chromatograms demonstrating resolution or validated quantification of both components.

  • LC-MS, ESI-MS or high-resolution MS identity confirmation for each peptide.

  • Exact sequences, stereochemistry and terminal groups.

  • Confirmation that the CJC-1295 component is No DAC.

  • Individual active content: nominally 5 mg per component.

  • Blend homogeneity and total net content.

  • Residual-solvent results from synthesis and purification.

  • Water or residual-moisture content, where measured.

  • Heavy-metal or elemental-impurity results where included in the quality programme.

  • Lot number, manufacture date, retest date and storage requirements.

CJC-1295 No DAC is commonly reported as C₁₅₂Hβ‚‚β‚…β‚‚Nβ‚„β‚„Oβ‚„β‚‚ with average molecular mass approximately 3,367.9 Da. Ipamorelin is commonly reported as Cβ‚ƒβ‚ˆH₄₉N₉Oβ‚… with average molecular mass approximately 711.9 Da.pubchem.ncbi.nlm.nih+2

Both components are normally supplied as white to off-white lyophilised solids. Visual inspection cannot confirm identity, purity or blend uniformity. Analytical release should combine appearance assessment, individual HPLC quantification and mass-spectral confirmation.

High purity is essential because the blend contains two peptides with very different sizes, charge distributions and ionisation characteristics. CJC-1295-related truncations or DAC-containing impurities may be difficult to identify if the product is tested only by a generic blend assay. Ipamorelin may also be affected by incorrect stereochemistry, incomplete amidation or substitution-related impurities.

Principal Laboratory Applications and Research Methodologies

This blend is suitable for controlled laboratory research involving peptide analytics, GHRH- and ghrelin-receptor-related assay development, formulation science and in vitro model systems. All applications should be conducted by qualified personnel within an appropriately governed university, CRO, pharmaceutical R&D or analytical laboratory.

Individual-component RP-HPLC and LC-MS analysis. The primary analytical requirement is separation and quantification of both peptides. Because CJC-1295 No DAC is much larger than Ipamorelin, a single generic chromatographic method may require significant optimisation. Separate reference solutions or orthogonal confirmation may be appropriate.

Peptide identity and impurity profiling. Laboratories may monitor truncated CJC-1295 products, DAC-related species, oxidation products, incomplete amidation and Ipamorelin-related impurities. LC-MS or LC-HRMS should be used to confirm molecular identity rather than relying only on retention time.

In vitro receptor-signalling models. Verified individual components may be assessed in controlled cell-free or cellular systems involving GHRH-receptor or ghrelin-receptor pathways. Blend studies should include component-specific controls so that observed responses can be attributed to the correct peptide.

Blend homogeneity and stability research. Laboratories may examine whether the two components remain uniformly distributed and analytically stable during storage, dilution and sample preparation. Stability-indicating methods should track each peptide separately, as the larger CJC-1295 component and smaller Ipamorelin component may degrade or adsorb at different rates.

The stated 10 mg total contains nominally 5 mg of each component. Using the commonly reported molecular masses, 5 mg CJC-1295 No DAC corresponds to approximately 1.49 Β΅mol, while 5 mg Ipamorelin corresponds to approximately 7.02 Β΅mol. The blend is therefore equimass, not equimolar. This distinction should be made clear in technical procurement documents.

No final concentration should be stated without a specified reconstitution volume, salt form, purity, moisture content and validated preparation method. A blend should not be represented as a single molecular species.

Compound Stability, Optimal Storage, and Safe Handling Protocols

The combined lyophilised material should remain sealed, dry and protected from light until required for a validated laboratory procedure. Research guidance commonly recommends low-temperature storage, frequently around βˆ’20Β°C, although the actual CoA should take precedence.apexlab+1

Recommended controls include:

  • Store unopened lyophilised blend at approximately βˆ’20Β°C unless the CoA specifies otherwise.

  • Consider βˆ’80Β°C for extended archival storage where supported by the stability programme.

  • Keep the vial tightly closed, dry and protected from direct light.

  • Allow a sealed vial to reach room temperature before opening to minimise condensation.

  • Use low-binding tubes where adsorption could affect recovery.

  • Prepare aliquots only when validated for the blend and intended assay.

  • Store short-term aqueous solutions at 2–8Β°C only where validated.

  • Use frozen aliquots for longer-term solution storage where supported by stability data.

  • Avoid repeated freeze–thaw cycles.

  • Monitor both peptide components separately during stability studies.

  • Record blend ratio, solvent, concentration, preparation date, operator and storage history.

The two peptides may show different dissolution, adsorption and degradation behaviour. A solution that appears clear may still have lost one component preferentially. Blend integrity should therefore be assessed by component-resolved HPLC and LC-MS.

Reconstitution should be performed using a validated laboratory procedure. Add the selected solvent gradually and mix gently. Avoid vigorous agitation unless its compatibility has been demonstrated. If precipitation, turbidity or unexpected chromatographic changes occur, investigate the material before use.

Handling should follow the current SDS and institutional chemical-risk assessment. Appropriate precautions generally include a certified fume hood or suitable local containment, nitrile gloves, safety goggles and a laboratory coat. Avoid aerosol generation and direct contact with the powder or solution. Dispose of contaminated materials through approved institutional chemical and laboratory-waste procedures.

Technical Specifications and Molecular Attributes

Attribute CJC-1295 No DAC / Mod-GRF (1-29) Ipamorelin
Product quantity 5 mg 5 mg
Blend total 10 mg 10 mg
Sequence Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NHβ‚‚; verify batch sequence Aib-His-D-2-Nal-D-Phe-Lys-NHβ‚‚
Residue count 29 residues 5 residues
IUPAC name Complex peptide name should be confirmed on the CoA; sequence notation is preferred Complex peptide name should be confirmed on the CoA; sequence notation is preferred
CAS Registry Number 863288-34-0 is widely reported 170851-70-4
Molecular formula C₁₅₂Hβ‚‚β‚…β‚‚Nβ‚„β‚„Oβ‚„β‚‚ Cβ‚ƒβ‚ˆH₄₉N₉Oβ‚…
Average molecular mass Approximately 3,367.9–3,367.95 g/mol Approximately 711.9 g/mol
Physical state and colour Lyophilised white to off-white powder Lyophilised white to off-white powder
Solubility profile Method-dependent; solvent and buffer compatibility require validation Method-dependent; solvent and buffer compatibility require validation
Typical purity Proposed target β‰₯99.0% by RP-HPLC, component-specific Proposed target β‰₯99.0% by RP-HPLC, component-specific
Identity testing LC-MS, LC-HRMS and RP-HPLC LC-MS, LC-HRMS and RP-HPLC
Long-term storage Typically βˆ’20Β°C, sealed and protected from light and moisture Typically βˆ’20Β°C, sealed and protected from light and moisture

The blend is equimass rather than equimolar: each peptide is present at 5 mg, but their molecular masses differ substantially. CJC-1295 No DAC must also be distinguished from DAC-conjugated CJC-1295, which is a different chemical entity.apexlab+2

Pharma Research .eu: Your Premier EU Vendor for High-Purity Reagents

Pharma Research .eu can position this product as a documented European dual-peptide laboratory reagent for analytical chemists, biochemists and laboratory managers. The product file should include separate CoA results for the 5 mg CJC-1295 No DAC component and the 5 mg Ipamorelin component, together with sequence information, LC-MS identity, blend homogeneity, SDS and storage instructions.

Any claim that Pharma Research .eu operates an ISO 9001-certified quality-management system should be supported by a current certificate identifying the issuing body, scope and validity. Claims concerning discreet or temperature-controlled logistics across EU member states should likewise be verified for the destination, carrier route, packaging and applicable transport requirements.

A quality-focused supplier should be able to discuss:

  • CJC-1295 No DAC versus DAC-conjugated CJC-1295.

  • The exact Modified GRF (1-29) sequence and terminal groups.

  • Ipamorelin’s Aib and D-2-Nal residues.

  • Component-specific RP-HPLC purity and LC-MS identity.

  • Equimass versus equimolar composition.

  • Blend homogeneity and net content.

  • Residual solvents, moisture and elemental-impurity reporting.

  • Storage, transport and documentation requirements.

Pharma Research .eu should therefore be described as a potential European source for sequence-verified CJC-1295 No DAC plus Ipamorelin, with vendor-specific certification and logistics claims verified through current records. The material is intended strictly for controlled laboratory research and analytical use by qualified personnel under applicable institutional procedures.

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Buy CJC1295 No DAC (MOD-GRF (1-29)) +Ipamorelin 10 mg (5mg+5mg)”

Your email address will not be published. Required fields are marked *

Shipping & Delivery

MAECENAS IACULIS

Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.

ADIPISCING CONVALLIS BULUM

  • Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
  • Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
  • Diam parturient dictumst parturient scelerisque nibh lectus.

Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisqueΒ vestibulum amet elit ut volutpat.